Research programme: bispecific antibody therapy - MAT Biopharma

Drug Profile

Research programme: bispecific antibody therapy - MAT Biopharma

Alternative Names: Anti-CD5/anti-CD32 bispecific antibody therapy - MAT Biopharma; Bispecific antibody cancer therapy - MAT Biopharma

Latest Information Update: 23 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MAT Biopharma
  • Class Bispecific antibodies
  • Mechanism of Action Apoptosis stimulants; CD5 antigen inhibitors; IgG receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 23 Feb 2011 Discontinued - Preclinical for Chronic lymphocytic leukaemia in France (Parenteral)
  • 13 Jun 2005 Preclinical trials in Chronic lymphocytic leukaemia in France (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top